Cargando…

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers

Mostrar otras versiones (1)

Background: Levels of neutralizing antibodies (NΑbs) against SARS-CoV-2 correlate with clinically relevant immune protection from COVID-19. However, a slight decline in antibody titers has become evident even at one month following the second BNT162b2 shot, whereas increased time since the second va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Trougakos, Ioannis P., Karalis, Vangelis, Ntanasis-Stathopoulos, Ioannis, Apostolakou, Filia, Gumeni, Sentiljana, Sklirou, Aimilia D., Skourti, Stamatia, Gavriatopoulou, Maria, Kastritis, Efstathios, Korompoki, Eleni, Papassotiriou, Ioannis, Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	203.Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701429/ http://dx.doi.org/10.1182/blood-2021-145074

Ejemplares similares

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study
por: Zirou, Christina, et al.
Publicado: (2023)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity
por: Wu, Jianghua, et al.
Publicado: (2021)

Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK
por: Shields, Adrian M, et al.
Publicado: (2021)

Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19
por: Corona De Lapuerta, Magdalena, et al.
Publicado: (2021)

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
por: Shree, Tanaya, et al.
Publicado: (2021)

Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial
por: Charania, Asad, et al.
Publicado: (2021)

Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections
por: Singh, Aditi, et al.
Publicado: (2021)

Lymphocyte Ratios Progressively Worsen in Non-Survivors of COVID-19
por: Alagbe, Adekunle Emmanuel, et al.
Publicado: (2021)

Early Immune Profile Assessment By Flow Cytometry Predicts Severe COVID-19 Pneumonia
por: Rial-Villavecchia, Abora, et al.
Publicado: (2021)

Prevalence of Allelic Variants and Clonality of IGHV1-69 Expressing B-Cells in Patients with Different Severity of COVID 19 Disease
por: Panovska-Stavridis, Irina, et al.
Publicado: (2021)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

Economic consequences for Medicaid of human immunodeficiency virus infection
por: Baily, Mary Ann, et al.
Publicado: (1990)

Medicaid home and community-based waivers for acquired immunodeficiency syndrome patients
por: Lindsey, Phoebe A., et al.
Publicado: (1990)

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study
por: De Ramón, Cristina, et al.
Publicado: (2020)

CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C
por: Utley, Adam, et al.
Publicado: (2020)

COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality
por: Niu, Alex, et al.
Publicado: (2020)

COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen
por: Ihlow, Jana, et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain
por: Cabirta, Alba, et al.
Publicado: (2020)

The Correlation between Absolute Lymphocyte Counts and Clinical Outcomes in COVID-19 Patients
por: Goldberg, Mayer, et al.
Publicado: (2020)

Detailed Immunophenotypic Profiling of Peripheral Blood Immune Cells in Patients with Hematologic Malignancies after Sars-Cov-2 Infection
por: Lutfi, Forat, et al.
Publicado: (2020)

Report of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Four Patients with Hematological Malignancies Treated at King Fahad Medical City, Riyadh, Saudi Arabia
por: Motabi, Ibraheem H, et al.
Publicado: (2016)

The ACE2 Receptor for COVID-19 Entry Is Expressed on the Surface of Hematopoietic Stem/Progenitor Cells and Endothelial Progenitors As Well As Their Precursor Cells and Becomes Activated in Nlrp3 Inflammasome-Dependent Manner By Virus Spike Protein - a Potential Pathway Leading to a “Cytokine Storm”
por: Kucia, Magdalena, et al.
Publicado: (2020)

Atypical Peripheral Blood Cell Morphology in COVID-19 (Sars-CoV-2) Patients from Mount Sinai Health System in New York City
por: Salib, Christian, et al.
Publicado: (2020)

Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance
por: Maia, Catarina, et al.
Publicado: (2020)

Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases
por: Cattaneo, Chiara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n1utgrstjfquloglv5rchv0jn3